$8.70
1.99% yesterday
Nasdaq, Dec 24, 10:22 pm CET
ISIN
US87583X1090
Symbol
TNGX

Tango Therapeutics Inc Stock price

$8.70
-1.63 15.78% 1M
+3.34 62.31% 6M
+5.61 181.55% YTD
+5.66 186.18% 1Y
+0.87 11.11% 3Y
-2.56 22.70% 5Y
-1.53 14.96% 10Y
-1.53 14.96% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.17 1.99%
ISIN
US87583X1090
Symbol
TNGX
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.0b
Net debt
positive
Cash
$152.8m
Shares outstanding
111.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
17.6 | 18.2
EV/Sales
15.3 | 15.9
EV/FCF
negative
P/B
7.3
Financial Health
Equity Ratio
63.3%
Return on Equity
-65.2%
ROCE
-57.6%
ROIC
-200.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$66.5m | $64.3m
EBITDA
$-107.9m | $-109.5m
EBIT
$-110.3m | $-115.2m
Net Income
$-100.5m | $-101.4m
Free Cash Flow
$-146.8m
Growth (TTM | estimate)
Revenue
53.3% | 52.8%
EBITDA
21.5% | 23.5%
EBIT
21.1% | 20.9%
Net Income
18.9% | 22.2%
Free Cash Flow
-19.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-162.3% | -170.4%
EBIT
-165.9%
Net
-151.2% | -157.8%
Free Cash Flow
-220.7%
More
EPS
$-0.9
FCF per Share
$-1.3
Short interest
28.6%
Employees
155
Rev per Employee
$270.0k
Show more

Is Tango Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Tango Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Tango Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Tango Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Tango Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
67 67
53% 53%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 43 43
1% 1%
64%
- Research and Development Expense 134 134
5% 5%
202%
-108 -108
21% 21%
-162%
- Depreciation and Amortization 2.42 2.42
3% 3%
4%
EBIT (Operating Income) EBIT -110 -110
21% 21%
-166%
Net Profit -101 -101
19% 19%
-151%

In millions USD.

Don't miss a Thing! We will send you all news about Tango Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tango Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST.
Neutral
GlobeNewsWire
29 days ago
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.
Positive
Seeking Alpha
about one month ago
Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancre...
More Tango Therapeutics Inc News

Company Profile

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Barbara Weber
Employees 155
Founded 2017
Website www.tangotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today